Ferumoxytol (Feraheme) Has Not Been Studied in First Trimester Pregnancy
There are no human studies evaluating ferumoxytol safety specifically in the first trimester, and current expert guidelines explicitly recommend avoiding all IV iron formulations prior to 13 weeks gestation 1.
Evidence from FDA Drug Label
The FDA label for Feraheme clearly states that "limited available data with ferumoxytol use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes" 2. The only available data comes from animal studies during organogenesis:
- In rabbits, ferumoxytol at 6 times the human dose caused fetal malformations and decreased fetal weights
- In rats, similar high doses caused decreased fetal weights
- At doses approximately 2 times the human dose, no maternal or fetal effects were observed in either species
Critically, the FDA label emphasizes that severe adverse reactions including circulatory failure and severe hypotension "may cause fetal bradycardia, especially during the second and third trimester" 2 - notably mentioning only second and third trimester, not first.
Expert Consensus Guidelines
The 2024 American Journal of Hematology expert consensus guidelines provide the most direct recommendation: "Avoid IV iron prior to 13 weeks gestation" 1. This applies to all IV iron formulations, including ferumoxytol. The guideline does note that ferumoxytol has been shown to be "safe and efficacious across a host of conditions associated with iron lack, including...pregnancy" 1, but this refers to pregnancy in general, not specifically the first trimester.
Limited Research Evidence
The available research on ferumoxytol in pregnancy does not address first trimester use:
- A 2023 randomized controlled trial compared ferumoxytol to oral iron in pregnant women with anemia, showing superior efficacy and good tolerability 3, but enrollment timing relative to gestational age was not specified
- A 2020 rhesus macaque study administered ferumoxytol at approximately gestational day 100 (mid-pregnancy equivalent) and found no negative impact on the maternal-fetal interface 4, but this was not first trimester
Clinical Implications
The absence of first trimester data, combined with animal teratogenicity at high doses and expert consensus to avoid use before 13 weeks, means ferumoxytol should not be used in the first trimester. The theoretical concerns include:
- Organogenesis vulnerability: The first trimester is the critical period for organ formation when teratogenic risks are highest
- Hypersensitivity risk: Severe maternal hypotension or anaphylactic reactions could compromise placental perfusion during critical early development
- Unknown placental transfer: While iron nanoparticles are generally too large for placental transfer, this has not been specifically studied in early pregnancy
If iron deficiency anemia requires treatment in the first trimester, oral iron supplementation remains the standard approach, with IV iron deferred until after 13 weeks gestation when the risk-benefit profile is better established 1.